Deltaran and plasma superoxide dismutase in rats
S. G. Dagaev, L. G. Kubarskaya, V. A. Kashuro · 2017 · Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22
Indexed 2026-11-09.
Related evidence maps: Sports performance ↗
Reported findings and study design
Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.
Male and female rats received intranasal Deltaran for five days and were compared with controls. The abstract reports six per group and measures plasma protein, lipids and antioxidant enzyme activity.
Protocol information
Intranasal Deltaran for five days. The abstract prints 150 mg/kg for the formulation. The unit and the mass of isolated DSIP are unconfirmed.
Protocol source ↗ · Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Plasma superoxide dismutase activity | +28.6% in males and +21.1% in females | Versus corresponding controls. · p<0.05 as reported |
| Plasma protein and total lipids | Protein +14.8% in males and total lipids +20.2% in females | Versus corresponding controls. The reverse sex-specific comparisons showed no reported difference. · p<0.05 as reported |
| Female plasma phospholipid share | −21.3% | Share of plasma lipids, a separate measure from total lipids. |
These biomarker changes describe the tested DSIP-plus-glycine formulation.
Source for the extracted data ↗ · Checked 2026-11-09
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Small conference experiment and an unusually high printed formulation dose. No performance, endurance or human endpoint was measured.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
Review depth: Reported methods, results and evidence limitations
Source access and review scope
Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
Recorded source-check date: 2026-11-09. This date does not imply a completed systematic review.
Source type: Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22
Citation and original source
Original source: S. G. Dagaev, L. G. Kubarskaya, V. A. Kashuro. Deltaran and plasma superoxide dismutase in rats Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22 2017.
Molekul research summary: https://molekul.io/research/dagaev-deltaran-sod-2017. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Deltaran
A formulation containing delta sleep-inducing peptide and glycine. The linked behavioral and blood-marker studies evaluated the formulation.
DSIP
A peptide first characterized in Swiss sleep research and later studied in Soviet/Russian analogue and stress-adaptation programs. Ordinary DSIP, modified analogues and piracetam combinations have distinct evidence.